Dosing underway in study of Mesoblast cell therapy in COVID-19

Mesoblast Limited (NASDAQ:MESO) is up 12% premarket on light volume in reaction to its announcement that the first participants have been dosed in a 300-subject Phase 2/3 clinical trial evaluating cell therapy remestemcel-L in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) on ventilator support.

The primary endpoint is all-cause mortality with 30 days of randomization compared to placebo plus standard-of-care treatment.

The company is developing remestemcel-L for various inflammatory conditions, including acute graft-versus-host disease. It works by downregulating production of pro-inflammatory proteins (cytokines) while increasing production of anti-inflammatory cytokines.

https://seekingalpha.com/news/3570022-dosing-underway-in-study-of-mesoblast-cell-therapy-in-covidminus-19